Bipolar disorder

Behavioral Genetics of the Mouse Volume II: Genetic Mouse Models of Neurobehavioral Disorders

Volumn , Issue , 2014, Pages 278-292

  Kara, Nirit ^a,b   Einat, Haim ^a,b,c  

^a Academic College of Tel Aviv Yafo   (Israel)

^b BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^c UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84953258493     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/CBO9781107360556     Document Type: Chapter

References (179)

1. Agam, G., Bersudsky, Y., Berry, G. T., et al. (2009) Knockout mice in understanding the mechanism of action of lithium. Biochem Soc Trans 37: 1121-1125.
2. Andreazza, A. C., Shao, L., Wang, J. F., and Young, L. T. (2010) Mitochondrial complex I activity and oxidative damage to mitochondrial proteins in the prefrontal cortex of patients with bipolar disorder. Arch Gen Psychiatry 67: 360-368.
3. Angst, J., Gamma, A., Sellaro, R., Lavori, P. W., and Zhang, H. (2003) Recurrence of bipolar disorders and major depression. A life-long perspective. Eur Arch Psychiatry Clin Neurosci 253: 236-240.
4. Avale, M. E., Falzone, T. L., Gelman, D. M., et al. (2004) Thedopamine D4 receptor is essential for hyperactivity and impaired behavioral inhibition in a mouse model of attention deicit/hyperactivity disorder. Mol Psychiatry 9: 718-726.
5. Bachmann, R. F., Schloesser, R. J., Gould, T. D., and Manji, H. K. (2005) Mood stabilizers target cellular plasticity and resilience cascades: Implications for the development of novel therapeutics. Mol Neurobiol 32: 173-202.
6. Bai, O., Zhang, H., and Li, X. M. (2004) Antipsychotic drugs clozapine and olanzapine upregulate bcl-2 mRNA and protein in rat frontal cortex and hippocampus. Brain Res 1010: 81-86.
7. Barbier, E. and Wang, J. B. (2009) Anti-depressant and anxiolytic like behaviors in PKCI/HINT1 knockout mice associated with elevated plasma corticosterone level. BMC Neurosci 10: 132.
8. Beaulieu, J. M. (2012) A role for Akt and glycogen synthase kinase-3 as integrators of dopamine and serotonin neurotransmission in mental health. J Psychiatry Neurosci 37: 7-16.
9. Begley, C. E., Annegers, J. F., Swann, A. C., et al. (2001) Thelifetime cost of bipolar disorder in the US: An estimate for new cases in 1998. Pharmacoeconomics 19: 483-495.
10. Bello, E. P., Mateo, Y., Gelman, D. M., et al. (2011) Cocaine supersensitivity and enhanced motivation for reward in mice lacking dopamine D2 autoreceptors. Nat Neurosci 14: 1033-1038.
11. Belmaker, R. H., Livne, A., Agam, G., et al. (1990) Role of inositol-1-phosphatase inhibition in the mechanism of action of lithium. Pharmacol Toxicol 66: 76-83.
12. Belmaker, R. H., Revazov, A., Bersudskey, Y., and Kofman, O. (1992) Inositol passes the blood brain behavior suiciently to reverse lithium Effects on behavior in rats. Clin Neuropharmacol 15: 606A-607A.
13. Benedetti, F., Barbini, B., Campori, E., et al. (2001) Sleep phase advance and lithium to sustain the antidepressant efect of total sleep deprivation in bipolar depression: New indings supporting the internal coincidence model? J Psychiatr Res 35: 323-329.
14. Benedetti, F., Fresi, F., Maccioni, P., and Smeraldi, E. (2008) Behavioural sensitization to repeated sleep deprivation in a mice model of mania. Behav Brain Res 187: 221-1217.
15. Berridge, M. J. (1989) The Albert Lasker Medical Awards. Inositol trisphosphate, calcium, lithium, and cell signaling. JAMA 262: 1834-1841.
16. Bersudsky, Y., Shaldubina, A., Agam, G., Berry, G. T., and Belmaker, R. H. (2008) Homozygote inositol transporter knockout mice show a lithium-like phenotype. Bipolar Disord 10: 453-459.
17. Bigos, K. L., Mattay, V. S., Callicott, J. H., et al. (2010) Genetic variation in CACNA1C afects brain circuitries related to mental illness. Arch Gen Psychiatry 67: 939-945.
18. Bloch, P. J., Weller, A. E., Doyle, G. A., et al. (2010) Association analysis between polymorphisms in the myo-inositol monophosphatase 2 (IMPA2) gene and bipolar disorder. Prog Neuropsychopharmacol Biol Psychiatry 34: 1515-1519.
19. Bowers, B. J., Collins, A. C., Tritto, T., and Wehner, J. M. (2000) Mice lacking PKC gamma exhibit decreased anxiety. Behav Genet 30: 111-121.
20. Brown, E. S. (2009) Effects of glucocorticoids on mood, memory, and the hippocampus. Treatment and preventive therapy. Ann NY Acad Sci 1179: 41-55.
21. Brown, E. S. and Chandler, P. A. (2001) Mood and cognitive changes during systemic corticosteroid therapy. Prim Care Companion J Clin Psychiatry 3: 17-21.
22. Calabrese, J. R., Hirschfeld, R. M., Reed, M., et al. (2003) Impact of bipolar disorder on a U. S. community sample. J Clin Psychiatry 64: 425-432.
23. Carlson, P. J., Singh, J. B., Zarate, C. A., Jr., Drevets, W. C., and Manji, H. K. (2006) Neural circuitry and neuroplasticity in mood disorders: Insights for novel therapeutic targets. NeuroRx 3: 22-41.
24. Chan, J. P., Unger, T. J., Byrnes, J., and Rios, M. (2006) Examination of behavioral deicits triggered by targeting Bdnf in fetal or postnatal brains of mice. Neuroscience 142: 49-58.
25. Chang, F., Steelman, L. S., Shelton, J. G., et al. (2003) Regulation of cell cycle progression and apoptosis by the Ras/Raf/MEK/ERK pathway (review). Int J Oncol 22: 469-480.
26. Chen, G., Henter, I. D., and Manji, H. K. (2010) Translational research in bipolar disorder: Emerging insights from genetically based models. Mol Psychiatry 15: 883-895.
27. Chen, G. and Manji, H. K. (2006) The extracellular signal-regulated kinase pathway: An emerging promising target for mood stabilizers. Curr Opin Psychiatry 19: 313-323.
28. Chen, G., Zeng, W. Z., Yuan, P. X., et al. (1999) Themood-stabilizing agents lithium and valproate robustly increase the levels of the neuroprotective protein bcl-2 in the CNS. J Neurochem 72: 879-882.
29. Cleary, C., Linde, J. A., Hiscock, K. M., et al. (2008) Antidepressive-like Effects of rapamycin in animal models: Implications for mTOR inhibition as a new target for treatment of afective disorders. Brain Res Bull 76: 469-473.
30. Cousins, D. A. and Young, A. H. (2007) Thearmamentarium of treatments for bipolar disorder: A review of the literature. Int J Neuropsychopharmacol 10: 411-431.
31. Crawley, J. N. (2000) What’sWrong with My Mouse? Behavioral Phenotyping of Transgenic and Knockout Mice. NewYork: Wiley-Liss.
32. Cryns, K., Shamir, A., Shapiro, J., et al. (2007) Lack of lithium-like behavioral and molecular Effects in IMPA2 knockout mice. Neuropsychopharmacology 32: 881-891.
33. Cryns, K., Shamir, A., Van Acker, N., et al. (2008) IMPA1 is essential for embryonic development and lithium-like pilocarpine sensitivity. Neuropsychopharmacology 33: 674-684.
34. Dao, D. T., Mahon, P. B., Cai, X., et al. (2010) Mood disorder susceptibility gene CACNA1C modiies mood-related behaviors in mice and interacts with sex to inluence behavior in mice and diagnosis in humans. Biol Psychiatry 68: 801-810.
35. Diazgranados, N., Ibrahim, L., Brutsche, N. E., et al. (2010) A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression. Arch 67: 793-802.
36. Dluzen, D. E., Gao, X., Story, G. M., et al. (2001) Evaluation of nigrostriatal dopaminergic function in adult +/+ and +/-BDNF mutant mice. Exp Neurol 170: 121-128.
37. Dzirasa, K., Coque, L., Sidor, M. M., et al. (2010) Lithium ameliorates nucleus accumbens phase-signaling dysfunction in a genetic mouse model of mania. J Neurosci 30: 16314-16323.
38. Einat, H. (2007) Diferent behaviors and diferent strains: Potential new ways to model bipolar disorder. Neurosci Biobehav Rev 31: 850-857.
39. Einat, H. (2010) Strategies for the development of animal models for bipolar disorder: New opportunities and new challenges. In C. Zarate and K. H. Manji (eds) Behavioral Neurobiology of Bipolar Disorder and its Treatment. Berlin: Springer.
40. Einat, H., Kofman, O., Itkin, O., Lewitan, R. J., and Belmaker, R. H. (1998) Augmentation of lithium’s behavioral efect by inositol uptake inhibitors. J Neural Transm 105: 31-38.
41. Einat, H. and Manji, H. K. (2006) Cellular plasticity cascades: Gene to behavior pathways in animal models of bipolar disorder. Biol Psychiatry 59: 1960-1971.
42. Einat, H., Manji, H. K., Gould, T. D., Du, J., and Chen, G. (2003a) Possible involvement of the ERK signaling cascade in bipolar disorder: Behavioral leads from the study of mutant mice. Drug News Perspect 16: 453-563.
43. Einat, H., Shaldubina, A., Bersudskey, Y., and Belmaker, R. H. (2007a) Prospects for the development of animal models for the study of bipolar disorder. In J. C. Soares and A. Young (eds) Bipolar Disorder: Basic Mechanisms and herapeutic Implications, 2nd edn. New York: Taylor & Francis.
44. Einat, H., Yuan, P., Gould, T. D., et al. (2003b) Therole of the extracellular signal-regulated kinase signaling pathway in mood modulation. J Neurosci 23: 7311-7316.
45. Einat, H., Yuan, P., and Manji, H. K. (2005) Increased anxiety-like behaviors and mitochondrial dysfunction in mice with targeted mutation of the Bcl-2 gene: Further support for the involvement of mitochondrial function in anxiety disorders. Behav Brain Res 165: 172-180.
46. Einat, H., Yuan, P., Szabo, S. T., Dogra, S., and Manji, H. K. (2007b) Protein kinase C inhibition by tamoxifen antagonizes manic-like behavior in rats: Implications for the development of novel therapeutics for bipolar disorder. Neuropsychobiology 55: 123-131.
47. Ellenbroek, B. A. and Cools, A. R. (1990) Animal models with construct validity for schizophrenia. Behav Pharmacol 1: 469-490.
48. Engel, S. R., Creson, T. K., Hao, Y., et al. (2009) Theextracellular signal-regulated kinase pathway contributes to the control of behavioral excitement. Mol Psychiatry 14: 448-461.
49. Fitzgerald, P. J., Barkus, C., Feyder, M., et al. (2010) Does gene deletion of AMPA GluA1 phenocopy features of schizoafective disorder? Neurobiol Dis 40: 608-621.
50. Flaisher-Grinberg, S. and Einat, H. (2010) Strain-specific battery of tests for domains of mania: Effects of valproate, lithium and imipramine. Front Psychopharmacology 1: 1-10.
51. Flaisher-Grinberg, S., Kronfeld-Schor, N., and Einat, H. (2010) Models of mania: From facets to domains and from animal models to model animals. J Psychopharmacology 24: 437-438.
52. Friedman, E., Hoau Yan, W., Levinson, D., Connell, T. A., and Singh, H. (1993) Altered platelet protein kinase C activity in bipolar afective disorder, manic episode. Biol Psychiatry 33: 520-525.
53. Fukada, M., Hanai, A., Nakayama, A., et al. (2012) Loss of deacetylation activity of Hdac6 afects emotional behavior in mice. PLoS One 7: E30924.
54. Gessa, G. L., Pani, L., Fadda, P., and Fratta, W. (1995) Sleep deprivation in the rat: An animal model of mania. Eur Neuropsychopharmacol 5: 89-93.
55. Geyer, M. A., Krebs-homson, K., Braf, D. L., and Swerdlow, N. R. (2001) Pharmacological studies of prepulse inhibition models of sensorimotor gating deicits in schizophrenia: A decade in review. Psychopharmacology 156: 117-154.
56. Goodwin, F. K. and Jamison, K. R. (1990) Manic Depressive Illness. NewYork: Oxford University Press.
57. Gould, T. D. and Einat, H. (2007) Animal models of bipolar disorder and mood stabilizer efficacy: A critical need for improvement. Neurosci Biobehav Rev 31: 825-831.
58. Gould, T. D., Einat, H., Bhat, R., and Manji, H. K. (2004) AR-A014418, a selective GSK-3 inhibitor, produces antidepressant-like Effects in the forced swim test. Int J Neuropsychopharmacol 7: 387-390.
59. Gould, T. D., Einat, H., O’Donnell, K. C., et al. (2007a) Beta-catenin overexpression in the mouse brain phenocopies lithium-sensitive behaviors. Neuropsychopharmacology 32: 2173-2183.
60. Gould, T. D. and Gottesman, I. I. (2006) Psychiatric endophenotypes and the development of valid animal models. Genes Brain Behav 5: 113-119.
61. Gould, T. D. and Manji, H. K. (2004) Themolecular medicine revolution and psychiatry: Bridging the gap between basic neuroscience research and clinical psychiatry. J Clin Psychiatry 65: 598-604.
62. Gould, T. D., O’Donnell, K. C., Picchini, A. M., and Manji, H. K. (2007b) Strain diferences in lithium attenuation of d-amphetamine-induced hyperlocomotion: A mouse model for the genetics of clinical response to lithium. Neuropsychopharmacology 32: 1321-1333.
63. Gould, T. D., O’Donnell, K. C., Picchini, A. M., et al. (2008) Generation and behavioral characterization of [beta]-catenin forebrain-specific conditional knock-out mice. Behav Brain Res 189: 117.
64. Gould, T. D., Picchini, A. M., Einat, H., and Manji, H. K. (2006) Targeting glycogen synthase kinase-3 in the CNS: Implications for the development of new treatments for mood disorders. Curr Drug Targets 7: 1399-1409.
65. Greenlund, L. J., Korsmeyer, S. J., and Johnson E. M., Jr. (1995) Role of BCL-2 in the survival and function of developing and mature sympathetic neurons. Neuron 15: 649-661.
66. Hara, A., Hirose, Y., Wang, A., et al. (1996) Localization of Bax and Bcl-2 proteins, regulators of programmed cell death, in the human central nervous system. Virchows Arch 429: 249-253.
67. Harvey, A. G. (2008) Sleep and circadian rhythms in bipolar disorder: Seeking synchrony, harmony, and regulation. Am J Psychiatry 165: 820-829.
68. Howell, M. P. and Muglia, L. J. (2006) Effects of genetically altered brain glucocorticoid receptor action on behavior and adrenal axis regulation in mice. Front Neuroendocrinol 27: 275-284.
69. Huang, E. J. and Reichardt, L. F. (2001) Neurotrophins: Roles in neuronal development and function. Ann Rev Neurosci 24: 677-736.
70. Huang, Y. Y., Peng, C. H., Yang, Y. P., et al. (2007) Desipramine activated Bcl-2 expression and inhibited lipopolysaccharide-induced apoptosis in hippocampus-derived adult neural stem cells. J Pharmacol Sci 104: 61-72.
71. Insel, T. R. (2007) From animal models to model animals. Biol Psychiatry 62: 1337-1339.
72. Jasmin, L., Narasaiah, M., and Tien, D. (2006) Noradrenaline is necessary for the hedonic properties of addictive drugs. Vascul Pharmacol 45: 243-250.
73. Kaidanovich-Beilin, O., Milman, A., Weizman, A., Pick, C. G., and Eldar-Finkelman, H. (2004) Rapid antidepressive-like activity of specific glycogen synthase kinase-3 inhibitor and its efect on beta-catenin in mouse hippocampus. Biol Psychiatry 55: 781-784.
74. Kakefuda, K., Oyagi, A., Ishisaka, M., et al. (2010) Diacylglycerol kinase beta knockout mice exhibit lithium-sensitive behavioral abnormalities. PLoS One 5: E13447.
75. Kalinichev, M. and Dawson, L. A. (2011) Evidence for antimanic eicacy of glycogen synthase kinase-3 (GSK-3) inhibitors in a strain specific model of acute mania. Int J Neuropsychopharmacol 6: 1-17.
76. Karin, M. (1996) Theregulation of AP-1 activity by mitogen-activated protein kinases. Philos Trans R Soc Lond B Biol Sci 351: 127-134.
77. Kasahara, T., Kubota, M., Miyauchi, T., et al. (2006) Mice with neuron-specific accumulation of mitochondrial DNA mutations show mood disorder-like phenotypes. Mol Psychiatry 11: 577-593.
78. Kernie, S. G., Liebl, D. J., and Parada, L. F. (2000) BDNF regulates eating behavior and locomotor activity in mice. EMBO J 19: 1290-1300.
79. Klein, P. S. and Melton, D. A. (1996) A molecular mechanism for the efect of lithium on development. Proc Natl Acad Sci USA 93: 8455-8459.
80. Kofman, O., Belmaker, R. H., Grisaru, N., et al. (1991) Myo-inositol attenuates two specific behavioral Effects of acute lithium in rats. Psychopharmacol Bull 27: 185-190.
81. Kripke, D., Nievergelt, C., Joo, E. J., Shekhtman, T., and Kelsoe, J. (2009) Circadian polymorphisms associated with afective disorders. J Circad Rhythm 7: 2.
82. Kronfeld-Schor, N. and Einat, H. (2012) Circadian rhythms and depression: Human psychopathology and animal models. Neuropharmacology 62: 101-114.
83. Kupfer, D. J. (2005) Theincreasing medical burden in bipolar disorder. JAMA 293: 2528-2530.
84. Large, C. H., Einat, H., and Mahableshwarkar, A. R. (2008) Developing therapeutics for bipolar disorder: From animal models to the clinic. In R. A. McArthur and F. Borsini (eds) Animal and Translational Models for CNS Drug Discovery. Amsterdam: Elsevier.
85. Le-Niculescu, H., McFarland, M. J., Ogden, C. A., et al. (2008) Phenomic, convergent functional genomic, and biomarker studies in a stress-reactive genetic animal model of bipolar disorder and co-morbid alcoholism. Am J Med Genet B Neuropsychiatr Genet 147B: 134-166.
86. Lee, S. Y., Chen, S. L., Chang, Y. H., et al. (2012) TheALDH2 and 5-HT2A genes interacted in bipolar-I but not bipolar-II disorder. Prog Neuropsychopharmacol Biol Psychiatry 38: 247-251.
87. Li, X., Liu, M., Cai, Z., andWang, G. (2010) Regulation of glycogen synthase kinase-3 during bipolar mania treatment. Bipolar Disord 12: 741-752.
88. Lien, R., Flaisher-Grinberg, S., Cleary, C., Hejny, M., and Einat, H. (2008) Behavioral Effects of Bcl-2 deiciency: Implications for afective disorders. Pharmacol Rep 60: 490-498.
89. Longoni, R., Spina, L., Vinci, S., and Acquas, E. (2011) The MEK inhibitor SL327 blocks acquisition but not expression of lithium-induced conditioned place aversion: A behavioral and immunohistochemical study. Psychopharmacology 216: 63-73.
90. Lucki, I., Dalvi, A., and Mayorga, A. J. (2001) Sensitivity to the Effects of pharmacologically selective antidepressants in diferent strains of mice. Psychopharmacology 155: 315-322.
91. Luo, C., Xu, H., and Li, X. M. (2004) Post-stress changes in BDNF and Bcl-2 immunoreactivities in hippocampal neurons: Effect of chronic administration of olanzapine. Brain Res 1025: 194-202.
92. Lyon, M. (1991) Animal models of mania and schizophrenia. In P. Willner (ed.) Behavioral Models in Psychopharmacology: Heoretical, Industrial and Clinical Perspectives. Cambridge: Cambridge University Press.
93. Lyons, W. E., Mamounas, L. A., Ricaurte, G. A., et al. (1999) Brain-derived neurotrophic factor-deicient mice develop aggressiveness and hyperphagia in conjunction with brain serotonergic abnormalities. Proc Natl Acad Sci USA 96: 15239-15244.
94. Machado-Vieira, R., Ibrahim, L., Henter, I. D., and Zarate, C. A., Jr. (2012) Novel glutamatergic agents for major depressive disorder and bipolar disorder. Pharmacol Biochem Behav 100: 678-687.
95. Machado-Vieira, R., Kapczinski, F., and Soares, J. C. (2004) Perspectives for the development of animal models of bipolar disorder. Prog Neuropsychopharmacol Biol Psychiatry 28: 209-224.
96. Maeng, S., Hunsberger, J. G., Pearson, B., et al. (2008) BAG1 plays a critical role in regulating recovery from both manic-like and depression-like behavioral impairments. Proc Natl Acad Sci USA 105: 8766-8771.
97. Malkesman, O., Austin, D. R., Chen, G., and Manji, H. K. (2009a) Reverse translational strategies for developing animal models of bipolar disorder. Dis Model Mech 2: 238-245.
98. Malkesman, O., Scattoni, M. L., Paredes, D., et al. (2009b) The female urine sniing test: A novel approach for assessing reward-seeking behavior in rodents. Biol Psychiatry 67: 864-871.
99. Manji, H. K. and Duman, R. S. (2001) Impairments of neuroplasticity and cellular resilience in severe mood disorders: Implications for the development of novel therapeutics. Psychopharmacol Bull 35: 5-49.
100. Manji, H. K., Moore, G. J., and Chen, G. (2000) Lithium up-regulates the cytoprotective protein Bcl-2 in the CNS in vivo: A role for neurotrophic and neuroprotective Effects in manic depressive illness. J Clin Psychiatry 61: 82-96.
101. McEachron, D. L., Kripke, D. F., Sharp, F. R., Lewy, A. J., and McClellan, D. E. (1985) Lithium Effects on selected circadian rhythms in rats. Brain Res Bull 15: 347-350.
102. McIntyre, R. S. (2010) Pharmacology and eicacy of asenapine for manic and mixed states in adults with bipolar disorder. Expert Rev Neurother 10: 645-649.
103. McIsaac, S. A. and Young, A. H. (2009) The role of hypothalamic pituitary-adrenal axis dysfunction in the etiology of depressive disorders. Drugs Today 45: 127-133.
104. McKinney, W. T., Jr. and Bunney, W. E., Jr. (1969) Animal model of depression. I. Review of evidence: Implications for research. Arch Gen Psychiatry 21: 240-248.
105. Meltzer, H. Y., Arora, R. C., and Goodnick, P. (1983) Effect of lithium carbonate on serotonin uptake in blood platelets of patients with affective disorders. J Afect Disord 5: 215-221.
106. Mendels, J., Frazer, A., Fitzgerald, R. G., Ramsey, T. A., and Stokes, J. W. (1972) Biogenic amine metabolites in cerebrospinal fluid of depressed and manic patients. Science 175: 1380-1382.
107. Merikangas, K. R., Akiskal, H. S., Angst, J., et al. (2007) Lifetime and 12-month prevalence of bipolar spectrum disorder in the National Comorbidity Survey replication. Arch Gen Psychiatry 64: 543-552.
108. Michaud, C. M., Murray, C. J., and Bloom, B. R. (2001) Burden of disease-implications for future research. JAMA 285: 535-539.
109. Mitchell, K. J., Huang, Z. J., Moghaddam, B., and Sawa, A. (2011) Following the genes: A framework for animal modeling of psychiatric disorders. BMC Biol 9: 76.
110. Mitchell, P. J. and Redfern, P. H. (2005) Animal models of depressive illness: The importance of chronic drug treatment. Curr Pharm Des 11: 171-203.
111. Mokry, J. (1995) Experimental models and behavioural tests used in the study of Parkinson’s disease. Physiol Res 44: 143-150.
112. Muller, M. B., Zimmermann, S., Sillaber, I., et al. (2003) Limbic corticotropinreleasing hormone receptor 1 mediates anxiety-related behavior and hormonal adaptation to stress. Nat Neurosci 6: 1100-1107.
113. Murphy, D. L., Colburn, R. W., Davis, J. M., and Bunney, W. E., Jr. (1969) Stimulation by lithium of monoamine uptake in human platelets. Life Sci 8: 1187-1193.
114. Nestler, E. J., Gould, E., Manji, H., et al. (2002) Preclinical models: Status of basic research in depression. Biol Psychiatry 52: 503-528.
115. Nestler, E. J. and Hyman, S. E. (2010) Animal models of neuropsychiatric disorders. Nat Neurosci 13: 1161-1169.
116. Ng, W. X., Lau, I. Y., Graham, S., and Sim, K. (2009) Neurobiological evidence for thalamic, hippocampal and related glutamatergic abnormalities in bipolar disorder: A review and synthesis. Neurosci Biobehav Rev 33: 336-354.
117. Nievergelt, C. M., Kripke, D. F., Remick, R. A., et al. (2005) Examination of the clock gene Cryptochrome 1 in bipolar disorder: Mutational analysis and absence of evidence for linkage or association. Psychiatr Genet 15: 45-52.
118. O’Brien, W. T., Harper, A. D., Jove, F., et al. (2004) Glycogen synthase kinase-3 beta haploinsuiciency mimics the behavioral and molecular Effects of lithium. J Neurosci 24: 6791-6798.
119. Oford, J. (2012) Genetic approaches to a better understanding of bipolar disorder. Pharmacolher 133: 133-141.
120. Ohnishi, T., Watanabe, A., Ohba, H., et al. (2010) Behavioral analyses of transgenic mice harboring bipolar disorder candidate genes, IMPA1 and IMPA2. Neurosci Res 67: 86-94.
121. Pandey, G. N., Pandey, S. C., Ren, X., Dwivedi, Y., and Janicak, P. G. (2003) Serotonin receptors in platelets of bipolar and schizo affective patients: Effect of lithium treatment. Psychopharmacology 170: 115-123.
122. Perona, M. T., Waters, S., Hall, F. S., et al. (2008) Animal models of depression in dopamine, serotonin, and norepinephrine transporter knockout mice: Prominent Effects of dopamine transporter deletions. Behav Pharmacol 19: 566-574.
123. Post, R. M., Uhde, T. W., Roy-Byrne, P. P., and Jofe, R. T. (1987) Correlates of antimanic response to carbamazepine. Psychiatry Res 21: 71-83.
124. Prickaerts, J., Moechars, D., Cryns, K., et al. (2006) Transgenic mice overexpressing glycogen synthase kinase 3 beta: A putative model of hyperactivity and mania. J Neurosci 26: 9022-9029.
125. Redei, E. E., Ahmadiyeh, N., Baum, A. E., et al. (2001) Novel animal models of afective disorders. Semin Clin Neuropsychiatry 6: 43-67.
126. Rondi-Reig, L., Lemaigre Dubreuil, Y., Martinou, J. C., et al. (1997) Fear decrease in transgenic mice overexpressing bcl-2 in neurons. Neuroreport 8: 2429-2432.
127. Roybal, K., heobold, D., Graham, A., et al. (2007) Mania-like behavior induced by disruption of CLOCK. Proc Natl Acad Sci USA 104: 6406-6411.
128. Rozeboom, A. M., Akil, H., and Seasholtz, A. F. (2007) Mineralocorticoid receptor overexpression in forebrain decreases anxiety-like behavior and alters the stress response in mice. Proc Natl Acad Sci USA 104: 4688-4693.
129. Schank, J. R., Liles, L. C., andWeinshenker, D. (2008) Norepinephrine signaling through beta-adrenergic receptors is critical for expression of cocaine-induced anxiety. Biol Psychiatry 63: 1007-1012.
130. Schildkraut, J. J. (1974) Biogenic amines and afective disorders. Ann Rev Med 25: 333-348.
131. Schober, A. (2004) Classic toxin-induced animal models of Parkinson’s disease: 6-OHDA and MPTP. Cell Tissue Res 318: 215-224.
132. Seeman, P. (1987) Dopamine receptors and the dopamine hypothesis of schizophrenia. Synapse 1: 133-152.
133. Serretti, A. and Mandelli, L. (2008) Thegenetics of bipolar disorder: Genome “hot regions, ” genes, new potential candidates and future directions. Mol Psychiatry 13: 742-771.
134. Shaldubina, A., Buccafusca, R., Johanson, R. A. et al. (2007) Behavioural phenotyping of sodium-myo-inositol cotransporter heterozygous knockout mice with reduced brain inositol. Genes Brain Behav 6: 253-259.
135. Shaltiel, G., Chen, G., and Manji, H. K. (2007) Neurotrophic signaling cascades in the pathophysiology and treatment of bipolar disorder. Curr Opin Pharmacol 7: 22-26.
136. Shaltiel, G., Maeng, S., Malkesman, O., et al. (2008) Evidence for the involvement of the kainate receptor subunit GluR6 (GRIK2) in mediating behavioral displays related to behavioral symptoms of mania. Mol Psychiatry 13: 858-872.
137. Shaltiel, G., Shamir, A., Shapiro, J., et al. (2004) Valproate decreases inositol biosynthesis. Biol Psychiatry 56: 868-874.
138. Sjoholt, G., Ebstein, R. P., Lie, R. T., et al. (2004) Examination of IMPA1 and IMPA2 genes in manic-depressive patients: Association between IMPA2 promoter polymorphisms and bipolar disorder. Mol Psychiatry 9: 621-629.
139. Sjoholt, G., Gulbrandsen, A. K., Lovlie, R., et al. (2000) A human myo-inositol monophosphatase gene (IMPA2) localized in a putative susceptibility region for bipolar disorder on chromosome 18p11. 2: Genomic structure and polymorphism screening in manic-depressive patients. Mol Psychiatry 5: 172-180.
140. Smith, G. T. (2005) On construct validity: Issues of method and measurement. Psychol Assess 17: 396-408.
141. Smith, G. W., Aubry, J. M., Dellu, F., et al. (1998) Corticotropin releasing factor receptor 1-deicient mice display decreased anxiety, impaired stress response, and aberrant neuroendocrine development. Neuron 20: 1093-1102.
142. Soria, V., Martinez-Amoros, E., Escaramis, G., et al. (2010) Diferential association of circadian genes with mood disorders: CRY1 and NPAS2 are associated with unipolar major depression and CLOCK and VIP with bipolar disorder. Neuropsychopharmacology 35: 1279-1289.
143. Srinivasan, V., Smits, M., Spence, W., et al. (2006) Melatonin in mood disorders. World J Biol Psychiatry 7: 138-151.
144. Steketee, J. D. (1993) Injection of the protein kinase inhibitor H7 into the A10 dopamine region blocks the acute responses to cocaine: Behavioral and in vivo microdialysis studies. Neuropharmacology 32: 1289-1297.
145. Stork, C. and Renshaw, P. F. (2005) Mitochondrial dysfunction in bipolar disorder: Evidence from magnetic resonance spectroscopy research. Mol Psychiatry 10: 900-919.
146. Strauss, M. E. and Smith, G. T. (2008) Construct validity: Advances in theory and methodology. Ann Rev Clin Psychol 16: 16.
147. Taniguchi, S., Nakazawa, T., Tanimura, A., et al. (2009) Involvement of NMDAR2A tyrosine phosphorylation in depression-related behaviour. EMBO J 28: 3717-3729.
148. Tecott, L. H. and Nestler, E. J. (2004) Neurobehavioral assessment in the information age. Nat Neurosci 7: 462-466.
149. Timpl, P., Spanagel, R., Sillaber, I., et al. (1998) Impaired stress response and reduced anxiety in mice lacking a functional corticotropin-releasing hormone receptor 1. Nat Genet 19: 162-166.
150. Van Riezen, H., Schnieden, H., andWren, A. F. (1977) Olfactory bulb ablation in the rat: Behavioural changes and their reversal by antidepressant drugs. Br J Pharmacol 60: 521-528.
151. Varadarajulu, J., Lebar, M., Krishnamoorthy, G., et al. (2011) Increased anxiety-related behaviour in Hint1 knockout mice. Behav Brain Res 220: 305-311.
152. Watson, S., Gallagher, P., Ritchie, J. C., Ferrier, I. N., and Young, A. H. (2004) Hypothalamic-pituitary-adrenal axis function in patients with bipolar disorder. Br J Psychiatry 184: 496-502.
153. Wehr, T. A., Goodwin, F. K., Wirz-Justice, A., Breitmaier, J., and Craig, C. (1982) 48-hour sleep-wake cycles in manic-depressive illness: Naturalistic observations and sleep deprivation experiments. Arch Gen Psychiatry 39: 559-565.
154. Wehr, T. A., Sack, D. A., and Rosenthal, N. E. (1987) Sleep reduction as a inal common pathway in the genesis of mania. Am J Psychiatry 144: 201-204.
155. Wei, Q., Fentress, H. M., Hoversten, M. T., et al. (2012) Early-life forebrain glucocorticoid receptor overexpression increases anxiety behavior and cocaine sensitization. Biol Psychiatry 71: 224-231.
156. Wei, Q., Lu, X. Y., Liu, L., et al. (2004) Glucocorticoid receptor overexpression in forebrain: A mouse model of increased emotional lability. Proc Natl Acad Sci USA 101: 11851-11856.
157. Weinshenker, D., Miller, N. S., Blizinsky, K., Laughlin, M. L., and Palmiter, R. D. (2002) Mice with chronic norepinephrine deficiency resemble amphetamine-sensitized animals. Proc Natl Acad Sci USA 99: 13873-13877.
158. Williams, R. S., Cheng, L., Mudge, A. W., and Harwood, A. J. (2002) A common mechanism of action for three mood-stabilizing drugs. Nature 417: 292-295.
159. Willner, P. (1984) The validity of animal models of depression. Psychopharmacology 83: 1-16.
160. Willner, P. (1986) Validation criteria for animal models of human mental disorders: Learned helplessness as a paradigm case. Prog Neuropsychopharmacol Biol Psychiatry 10: 677-690.
161. Willner, P. (1990) Animal models of depression: An overview. Pharmacolher 45: 425-455.
162. Willner, P. (1991a) Animal models as simulations of depression. Trends Pharmacol Sci 12: 131-136.
163. Willner, P. (1991b) Behavioral models in psychopharmacology. In P. Willner (ed.) Behavioral Models in Psychopharmacology: Heoretical, Industrial and Clinical Perspectives. Cambridge: Cambridge University Press.
164. Willner, P. (1995a) Animal models of depression: Validity and applications. Adv Biochem Psychopharmacol 49: 19-41.
165. Willner, P. (1995b) Animal models of depression: Validity and applications. In G. L. Gessa, W. Fratta, L. Pani, and G. Serra (eds) Depression and Mania: From Neurobiology to Treatment. NewYork: Raven Press.
166. Willner, P., Muscat, R., and Papp, M. (1992) Chronic mild stress-induced anhedonia: A realistic animal model of depression. Neurosci Biobehav Rev 16: 525-534.
167. Wolfson, M., Einat, H., Bersudsky, Y., et al. (2000) Nordidemnin potently inhibits inositol uptake in cultured astrocytes and dose-dependently augments lithium’s proconvulsant efect in vivo. J Neurosci Res 60: 116-121.
168. Wu, J. B. and Shih, J. C. (2011) Valproic acid inducesmonoamine oxidase A via Akt/forkhead box O1 activation. Mol Pharmacol 80: 714-723.
169. Xu, F., Gainetdinov, R. R., Wetsel, W. C., et al. (2000) Mice lacking the norepinephrine transporter are supersensitive to psychostimulants. Nat Neurosci 3: 465-471.
170. Xu, H., Richardson, S. J., and Li, X. M. (2003) Dose-related Effects of chronic antidepressants on neuroprotective proteins BDNF, Bcl-2 and Cu/Zn-SOD in rat hippocampus. Neuropsychopharmacology 28: 53-62.
171. Yadav, R., Gupta, S. C., Hillman, B. G., et al. (2012) Deletion of glutamate delta-1 receptor in mouse leads to aberrant emotional and social behaviors. PLoS One 7: E32969.
172. Yan, X. B., Hou, H. L., Wu, L. M., Liu, J., and Zhou, J. N. (2007) Lithium regulates hippocampal neurogenesis by ERK pathway and facilitates recovery of spatial learning and memory in rats ater transient global cerebral ischemia. Neuropharmacology 53: 487-495.
173. Yildiz, A., Guleryuz, S., Ankerst, D. P., Ongur, D., and Renshaw, P. F. (2008) Protein kinase C inhibition in the treatment of mania: A double-blind, placebo-controlled trial of tamoxifen. Arch Gen Psychiatry 65: 255-263.
174. Young, J. W., Minassian, A., Paulus, M. P., Geyer, M. A., and Perry, W. (2007) A reverse-translational approach to bipolar disorder: Rodent and human studies in the Behavioral Pattern Monitor. Neurosci Biobehav Rev 31: 882-896.
175. Yuan, P. X., Huang, L. D., Jiang, Y. M., et al. (2001) The mood stabilizer valproic acid activates mitogen-activated protein kinases and promotes neurite growth. J Biol Chem 276: 31674-31683.
176. Zarate, C. A., Jr., Du, J., Quiroz, J., et al. (2003) Regulation of cellular plasticity cascades in the pathophysiology and treatment of mood disorders: Role of the glutamatergic system. Ann NY Acad Sci 1003: 273-291.
177. Zarate, C. A., Jr., Singh, J. B., Carlson, P. J., et al. (2006) A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry 63: 856-864.
178. Zarate, C. A., Jr., Singh, J. B., Carlson, P. J., et al. (2007) Eicacy of a protein kinase C inhibitor (tamoxifen) in the treatment of acute mania: A pilot study. Bipolar Disord 9: 561-570.
179. Zorner, B., Wolfer, D. P., Brandis, D., et al. (2003) Forebrain-specific trkB-receptor knockout mice: Behaviorally more hyperactive than “depressive. ” Biol Psychiatry 54: 972-982.